PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9790963-1 1998 Pioglitazone is a thiazolidinedione drug (TZD) which potently and specifically stimulates peroxisome proliferator-activated receptor gamma (PPAR gamma) and sensitizes cells to insulin. tzd 42-45 peroxisome proliferator activated receptor gamma Mus musculus 90-138 14764597-4 2004 Addition of PPARgamma ligand troglitazone (TZD) activated PPARgamma2 in proliferating hepatocytes and resulted in growth arrest accompanied by a down-regulation of proliferating cell nuclear antigen, cyclin D1, and beta-catenin expression. tzd 43-46 peroxisome proliferator activated receptor gamma Mus musculus 12-21 14764597-4 2004 Addition of PPARgamma ligand troglitazone (TZD) activated PPARgamma2 in proliferating hepatocytes and resulted in growth arrest accompanied by a down-regulation of proliferating cell nuclear antigen, cyclin D1, and beta-catenin expression. tzd 43-46 peroxisome proliferator activated receptor gamma Mus musculus 58-68 14764597-9 2004 These studies also showed a TZD-mediated inhibition of total and phospho-CREB(Ser133) levels, CREB promoter activity, and cAMP-response element-mediated transcription in PPARgamma hepatocytes. tzd 28-31 peroxisome proliferator activated receptor gamma Mus musculus 170-179 14764597-10 2004 Pretreatment of PPARgamma hepatocytes with okadaic acid, however, maintained higher total and phospho-CREB(Ser133) levels in the presence of TZD. tzd 141-144 peroxisome proliferator activated receptor gamma Mus musculus 16-25 9790963-1 1998 Pioglitazone is a thiazolidinedione drug (TZD) which potently and specifically stimulates peroxisome proliferator-activated receptor gamma (PPAR gamma) and sensitizes cells to insulin. tzd 42-45 peroxisome proliferator activated receptor gamma Mus musculus 140-150 33722775-0 2021 PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss. tzd 93-96 peroxisome proliferator activated receptor gamma Mus musculus 0-5 26362846-2 2015 Using a mouse model of Huntington"s Disease (HD), we recently showed that PPARgamma not only played a major function in preventing HD, but also oral intake of a PPARgamma agonist (thiazolidinedione, TZD) significantly reduced the formation of mutant Huntingtin (mHtt) aggregates in the brain (e.g., cortex and striatum). tzd 199-202 peroxisome proliferator activated receptor gamma Mus musculus 74-83 26362846-2 2015 Using a mouse model of Huntington"s Disease (HD), we recently showed that PPARgamma not only played a major function in preventing HD, but also oral intake of a PPARgamma agonist (thiazolidinedione, TZD) significantly reduced the formation of mutant Huntingtin (mHtt) aggregates in the brain (e.g., cortex and striatum). tzd 199-202 peroxisome proliferator activated receptor gamma Mus musculus 161-170 33722775-7 2021 Older gammaOTKO female mice are largely protected from TZD-induced bone loss providing proof of concept that PPARG in osteocytes can be pharmacologically targeted. tzd 55-58 peroxisome proliferator activated receptor gamma Mus musculus 109-114 29497032-6 2018 Moreover, the ability of the TZD class of anti-diabetic drugs to promote healthy visceral WAT remodeling is dependent on mural cell Pparg. tzd 29-32 peroxisome proliferator activated receptor gamma Mus musculus 132-137 30594432-2 2019 The X-ray crystallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics versus traditional TZD full agonists. tzd 140-143 peroxisome proliferator activated receptor gamma Mus musculus 43-52 33108252-3 2020 Specifically, treatment of obese mice with the PPARgamma agonist rosiglitazone (a thiazolidinedione, TZD) in combination with the GPR120 agonist compound A synergistically improves glucose tolerance and insulin sensitivity. tzd 101-104 peroxisome proliferator activated receptor gamma Mus musculus 47-56 23650507-5 2013 This novel TZD has low affinity for binding and activation of PPARgamma and has insulin-sensitizing effects in mouse models of diabetes and ability to lower glucose in Phase 2 clinical trials. tzd 11-14 peroxisome proliferator activated receptor gamma Mus musculus 62-71 27138164-0 2016 GQ-16, a TZD-Derived Partial PPARgamma Agonist, Induces the Expression of Thermogenesis-Related Genes in Brown Fat and Visceral White Fat and Decreases Visceral Adiposity in Obese and Hyperglycemic Mice. tzd 9-12 peroxisome proliferator activated receptor gamma Mus musculus 29-38 27138164-7 2016 METHODS: Male Swiss mice with obesity and hyperglycemia induced by high fat diet were treated with vehicle, rosiglitazone (4 mg/kg/d) or the TZD-derived partial PPARgamma agonist GQ-16 (40 mg/kg/d) for 14 days. tzd 141-144 peroxisome proliferator activated receptor gamma Mus musculus 161-170 28193552-4 2017 Eight compounds; TZD1, TZD-4, TZD-7, TZD-16, TZD-25, TZD-28, TZD-34, and TZD-37 demonstrated high affinity for PPAR-gamma binding site. tzd 17-20 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28193552-4 2017 Eight compounds; TZD1, TZD-4, TZD-7, TZD-16, TZD-25, TZD-28, TZD-34, and TZD-37 demonstrated high affinity for PPAR-gamma binding site. tzd 23-26 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28193552-4 2017 Eight compounds; TZD1, TZD-4, TZD-7, TZD-16, TZD-25, TZD-28, TZD-34, and TZD-37 demonstrated high affinity for PPAR-gamma binding site. tzd 23-26 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28193552-4 2017 Eight compounds; TZD1, TZD-4, TZD-7, TZD-16, TZD-25, TZD-28, TZD-34, and TZD-37 demonstrated high affinity for PPAR-gamma binding site. tzd 23-26 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28193552-4 2017 Eight compounds; TZD1, TZD-4, TZD-7, TZD-16, TZD-25, TZD-28, TZD-34, and TZD-37 demonstrated high affinity for PPAR-gamma binding site. tzd 23-26 peroxisome proliferator activated receptor gamma Mus musculus 111-121 26140591-4 2015 Moreover, genetically determined binding of PPARgamma accounts for mouse strain-specific transcriptional effects of TZD drugs, providing proof of concept for personalized medicine related to nuclear receptor genomic occupancy. tzd 116-119 peroxisome proliferator activated receptor gamma Mus musculus 44-53 21907283-6 2012 Treatment of R6/2 mice with an agonist of PPARgamma (thiazolidinedione, TZD) resulted in a beneficial effect on PPARgamma. tzd 72-75 peroxisome proliferator activated receptor gamma Mus musculus 42-51 22215652-1 2012 INT131 is a potent non-thiazolidinedione (TZD)-selective peroxisome proliferator-activated receptor-gamma modulator being developed for the treatment of type 2 diabetes. tzd 42-45 peroxisome proliferator activated receptor gamma Mus musculus 57-105 21907283-6 2012 Treatment of R6/2 mice with an agonist of PPARgamma (thiazolidinedione, TZD) resulted in a beneficial effect on PPARgamma. tzd 72-75 peroxisome proliferator activated receptor gamma Mus musculus 112-121 21907283-7 2012 By reducing Htt aggregates and thereby ameliorating the recruitment of PPARgamma into Htt aggregates, TZD treatment also elevated the availability of PPARgamma level and subsequently normalized the expression of downstream genes (including PGC-1alpha and several mitochondrial genes) in the cortex. tzd 102-105 peroxisome proliferator activated receptor gamma Mus musculus 71-80 21907283-7 2012 By reducing Htt aggregates and thereby ameliorating the recruitment of PPARgamma into Htt aggregates, TZD treatment also elevated the availability of PPARgamma level and subsequently normalized the expression of downstream genes (including PGC-1alpha and several mitochondrial genes) in the cortex. tzd 102-105 peroxisome proliferator activated receptor gamma Mus musculus 150-159 21907283-9 2012 Our results reveal that TZD and rosiglitazone may play a protective role in HD, and support the view that PPARgamma is a potential therapeutic target in HD. tzd 24-27 peroxisome proliferator activated receptor gamma Mus musculus 106-115 20668093-4 2010 Chronic treatment of R6/2 mice with an agonist of PPARgamma (thiazolidinedione, TZD) rescued progressive weight loss, motor deterioration, formation of mutant Htt aggregates, jeopardized global ubiquitination profiles, reduced expression of two neuroprotective proteins (brain-derived neurotrophic factor and Bcl-2) and shortened life span exhibited by these mice. tzd 80-83 peroxisome proliferator activated receptor gamma Mus musculus 50-59 21651979-6 2011 Treatment of R6/2 mice with an agonist of PPARgamma (thiazolidinedione, TZD) normalized the reduced PPARgamma transcript. tzd 72-75 peroxisome proliferator activated receptor gamma Mus musculus 42-51 21651979-6 2011 Treatment of R6/2 mice with an agonist of PPARgamma (thiazolidinedione, TZD) normalized the reduced PPARgamma transcript. tzd 72-75 peroxisome proliferator activated receptor gamma Mus musculus 100-109 21651979-10 2011 Treatment with PPARgamma agents (TZD and rosiglitazone) enhanced the function of PPARgamma, and might lead to therapeutic benefits. tzd 33-36 peroxisome proliferator activated receptor gamma Mus musculus 15-24 21651979-10 2011 Treatment with PPARgamma agents (TZD and rosiglitazone) enhanced the function of PPARgamma, and might lead to therapeutic benefits. tzd 33-36 peroxisome proliferator activated receptor gamma Mus musculus 81-90 20668093-5 2010 By reducing HTT aggregates and, thus, ameliorating the recruitment of PPARgamma into HTT aggregates, chronic TZD treatment also elevated the availability of the PPARgamma protein and subsequently normalized the expression of two of its downstream genes (the glucose transporter type 4 and PPARgamma coactivator-1 alpha genes). tzd 109-112 peroxisome proliferator activated receptor gamma Mus musculus 70-79 20668093-5 2010 By reducing HTT aggregates and, thus, ameliorating the recruitment of PPARgamma into HTT aggregates, chronic TZD treatment also elevated the availability of the PPARgamma protein and subsequently normalized the expression of two of its downstream genes (the glucose transporter type 4 and PPARgamma coactivator-1 alpha genes). tzd 109-112 peroxisome proliferator activated receptor gamma Mus musculus 161-170 20668093-6 2010 The protective effects described above appear to have been exerted, at least partially, via direct activation of PPARgamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPARgamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. tzd 140-143 peroxisome proliferator activated receptor gamma Mus musculus 113-122 20668093-6 2010 The protective effects described above appear to have been exerted, at least partially, via direct activation of PPARgamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPARgamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. tzd 140-143 peroxisome proliferator activated receptor gamma Mus musculus 210-219 20668093-6 2010 The protective effects described above appear to have been exerted, at least partially, via direct activation of PPARgamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPARgamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. tzd 192-195 peroxisome proliferator activated receptor gamma Mus musculus 113-122 19389808-2 2009 MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-gamma that is differentiated from the TZDs structurally, mechanistically, preclinically and clinically. tzd 35-38 peroxisome proliferator activated receptor gamma Mus musculus 69-124 20829614-1 2010 PPAR-gamma is a member of the nuclear hormone receptor superfamily of transcription factors, whose thiazolidinedione ligands (TZD) have been recently demonstrated to also possess anticancer properties in addition to their well-known insulin-sensitizer and glucose/lipid regulation activity. tzd 126-129 peroxisome proliferator activated receptor gamma Mus musculus 0-10 17007742-1 2006 AIM: To study whether T33, a new synthesized non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR) gamma/alpha dual agonist has an antidiabetic effect on ob/ob mice. tzd 68-71 peroxisome proliferator activated receptor gamma Mus musculus 117-121 16050946-1 2005 AIM: The purpose of this study was to characterize a novel, non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR)gamma agonist, RWJ-348260, via both in vitro and in vivo approaches. tzd 83-86 peroxisome proliferator activated receptor gamma Mus musculus 132-142 15735430-3 2005 Thiazolidenedione (TZD) ligands, which activate peroxisome proliferator-activated receptor-gamma (PPARgamma), have been shown to reduce TH1 inflammation in murine models of colitis, primarily in a preventative fashion. tzd 19-22 peroxisome proliferator activated receptor gamma Mus musculus 48-96 15735430-3 2005 Thiazolidenedione (TZD) ligands, which activate peroxisome proliferator-activated receptor-gamma (PPARgamma), have been shown to reduce TH1 inflammation in murine models of colitis, primarily in a preventative fashion. tzd 19-22 peroxisome proliferator activated receptor gamma Mus musculus 98-107